Atossa Therapeutics, Inc. (ATOS) NASDAQ
4.41
-0.14(-3.08%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.41
-0.14(-3.08%)
Currency In USD
Address
107 Spring Street
Seattle, WA 98104
United States of America (the)
Phone
206 588 0256
Sector
Healthcare
Industry
Biotechnology
Employees
15
First IPO Date
November 08, 2012
| Name | Title | Pay | Year Born |
| Steven C. Quay FCAP | Chairman, Chief Executive Officer & President | 1.02M | 1951 |
| Mark Daniel | Chief Financial Officer | 349,342 | 1977 |
| Richard Graydon | Interim Chief Medical Officer | 0 | N/A |
| Delly Behen | Senior Vice President of Business Operations | 0 | N/A |
| Janet Rose Rea MSPH | Senior Vice President of Research & Development | 0 | N/A |
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.